Opus Genetics Reports FY25 Results, Extends Cash Runway to 2028, and Secures October 2026 FDA PDUFA Date

summarizeSummary

Opus Genetics announced full-year 2025 financial results, a $25.0 million private placement extending its cash runway into 2028, and a key FDA PDUFA date of October 2026 for its Phentolamine Ophthalmic Solution.

check_boxKey Events

• Full Year 2025 Financial Results

  The company reported a net loss of $49.6 million for the year ended December 31, 2025, an improvement from a $57.5 million net loss in 2024. License and collaborations revenue increased to $14.2 million from $11.0 million in the prior year.

• Cash Runway Extended

  Opus Genetics secured approximately $25.0 million in gross proceeds through a private placement of equity securities subsequent to year-end. This financing, combined with existing cash, extends the company's cash resources to $70.1 million, expected to fund operations into the first half of 2028.

• FDA PDUFA Date Set for Phentolamine Ophthalmic Solution

  The FDA accepted the company's supplemental New Drug Application (sNDA) for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia and set a Prescription Drug User Fee Act (PDUFA) action date of October 17, 2026.

• Positive Early Clinical Data for OPGx-BEST1

  Favorable early safety and initial efficacy data from the Phase 1/2 trial (BIRD-1) for OPGx-BEST1 were presented, demonstrating good tolerability and early signals of functional vision improvement. Three-month results from the full Cohort 1 are expected mid-year 2026.

auto_awesomeAnalysis

This 8-K provides a comprehensive corporate update, including full-year 2025 financial results, a significant extension of the company's cash runway, and multiple positive pipeline advancements. The $25.0 million private placement substantially bolsters the balance sheet, providing capital into the first half of 2028. The FDA's acceptance of the supplemental New Drug Application (sNDA) for Phentolamine Ophthalmic Solution and the setting of an October 2026 PDUFA date is a critical regulatory milestone, signaling potential market approval for a new indication. Positive early clinical data for OPGx-BEST1 and ongoing progress for OPGx-LCA5 further de-risk the gene therapy pipeline. This filing follows a news release earlier today announcing the FDA sNDA acceptance.